Biogen Gets First US Tocilizumab Biosimilar

FDA Approves Bio-Thera-Partnered Tofidence; Biogen Is ‘Evaluating Launch Timeline’

Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said it was “currently evaluating the potential launch timeline.”

Tocilizumab vial in foreground
Biogen and Bio-Thera’s tocilizumab biosimilar has received FDA approval • Source: Shutterstock

More from Biosimilars

More from Products